| FORM PTO 1390 (REV 5-93) | US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTORNEY DOCKET NO. 2000_1561A |
|---|---|---|

**TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 USC 371**

U.S. APPLICATION NO. (if known see 37 CFR) 09/700843

| International Application No. PCT/JP99/02683 | International Filing Date May 21, 1999 | Priority Date Claimed May 22, 1998 |
|---|---|---|

**Title of Invention**
A VECTOR FOR GENE TRAP, AND A METHOD FOR GENE TRAPPING BY USING THE VECTOR

**Applicant(s) For DO/EO/US**
Tamas LUKACSOVICH, Zoltan ASZTALOS, Daisuke YAMAMOTO and Wakae AWANO

**Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:**

1. [X]   This is a **FIRST** submission of items concerning a filing under 35 USC 371.

2. []   This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.

3. []   This is an express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).

4. [X]   A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. [X]   A copy of the International Application as filed (35 USC 371(c)(2))
    a. [X] is transmitted herewith (required only if not transmitted by the International Bureau). **ATTACHMENT A**
    b. [X] has been transmitted by the International Bureau.
    c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).

6. []   A translation of the International Application into English (35 USC 371(c)(2)).

7. []   Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3)).
    a. [] are transmitted herewith (required only if not transmitted by the International Bureau).
    b. [] have been transmitted by the International Bureau.
    c. [] have not been made; however, the time limit for making such amendments has NOT expired.
    d. [] have not been made and will not be made.

8. []   A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).

9. [X]   An **unexecuted** oath or declaration of the inventor(s) (35 USC 371(c)(4)). **ATTACHMENT B**

10. []   A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

**Items 11. to 16. below concern other document(s) or information included:**
11. []   An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. []   An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X]   A FIRST preliminary amendment. **ATTACHMENT C**
    []   A SECOND or SUBSEQUENT preliminary amendment.
14. []   A substitute specification.
15. []   A change of power of attorney and/or address letter.
16. []   Other items or information:

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

| U.S. APPLICATION NO. (If known, see 37 CFR 1.5) NEW  09/700845  INTERNATIONAL APPLICATION NO. | | ATTORNEY DOCKET NO. 2000 1561A |
|---|---|---|

17. [X] The following fees are submitted

### BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

|  | CALCULATIONS | PTO USE ONLY |
|---|---|---|
| [X] Search Report has been prepared by the EPO or JPO . . . . . . . . . . . . . . . . . . . . . $860.00 | | |
| [] International preliminary examination fee paid to USPTO (37 CFR 1.482) . . . . . . . . $690.00 | | |
| [] No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) . . . . . . . . . . . . . $700.00 | | |
| [] Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . . . . . . . . . . . $1000.00 | | |
| [] International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-33(4) . . . . . . . . . . . . . . . . $100.00 | | |
| **ENTER APPROPRIATE BASIC FEE AMOUNT =** | $860.00 | |
| Surcharge of $130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)). | $ | |

| Claims | Number Filed | Number Extra | Rate | | |
|---|---|---|---|---|---|
| Total Claims | - 20 = | | X  $18.00 | $ | |
| Independent Claims | - 3 = | | X  $80.00 | $ | |
| Multiple dependent claim(s) (if applicable) | | | + $270.00 | $ | |
| **TOTAL OF ABOVE CALCULATIONS =** | | | | $860.00 | |
| Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)  − | | | | $ | |
| **SUBTOTAL =** | | | | $860.00 | |
| Processing fee of $130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).  + | | | | $ | |
| **TOTAL NATIONAL FEE =** | | | | $860.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) ($40 per property).  + | | | | $ | |
| **TOTAL FEES ENCLOSED =** | | | | $860.00 | |
| | | | Amount to be refunded: | $ | |
| | | | charged: | $ | |

- 2 -

a. [X]   A check in the amount of $860.00 to cover the above fees is enclosed.

b. []   Please charge my Deposit Account No. 23-0975 in the amount of $_____ to cover the above fees.  A duplicate copy of this sheet is enclosed.

c. [X]   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.  A duplicate copy of this sheet is enclosed.

*NOTE*:  Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

WENDEROTH, LIND & PONACK
2033 K St., N.W., Suite 800
Washington, D.C.  20006

Telephone:  (202) 721-8200
Facsimile:  (202) 721-8250

By _____
Warren M. Cheek, Jr.
Registration No. 33,367

November 21, 2000
WMC/dlk

Check No. ____40835____

2000_1561A

- 3 -

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of                  :

Tamas LUKACSOVICH et al.              :        **Attn: BOX PCT**

Serial No. NEW                        :        **Docket No. 2000-1561A**

Filed November 21, 2000               :

A VECTOR FOR GENE TRAP, AND A METHOD FOR
GENE TRAPPING BY USING THE VECTOR
**[Corresponding to PCT/JP99/02683
Filed May 21, 1999]**

———————

## PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
    Washington, DC 20231

Sir:

**Prior to calculating the filing fee**, please amend the above-identified application as follows:

### IN THE SPECIFICATION

Page 1,          immediately after the title, please insert:

-- This application is a 371 of PCT/JP99/02683 filed May 21, 1999. --

### IN THE CLAIMS

| | | |
|---|---|---|
| Claim 3, | line 1, | delete "or 2". |
| Claim 5, | line 1, | delete "or 2". |
| Claim 6, | line 1, | delete "or 2". |
| Claim 7, | line 1, | change "any one of claims 1-6" to -- claim 1 --. |
| Claim 8, | line 1, | change "any one of claims 1-7" to -- claim 1 --. |
| Claim 12, | line 1, | delete "or 11". |

ATTACHMENT C

| Claim 13, | line 1, | delete "or 11". |
| Claim 14, | line 1, | change "any one of claims 10 to 14" to -- claim 10 --. |
| Claim 15, | line 1, | change "any one of claims 10 to 15" to -- claim 10 --. |
| Claim 18, | line 1, | delete "or 17". |
| Claim 19, | line 1, | change "any one of claims 16 to 18" to -- claim 16 --. |

## REMARKS

The foregoing amendments are effected to amend the specification to reflect the 371 status. In addition, the multiple dependencies of the claims have been eliminated to remove the improper multiple dependencies and to reduce the PTO filing fee.

Favorable action on the merits is solicited.

Respectfully submitted,

Tamas LUKACSOVICH et al.

By _____
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C.
Telephone (202) 721-8200
Facsimile (202) 721-8250
November 21, 2000

# Description

## A Vector for Gene Trap, and A Method for Gene Trapping by Using The Vector

5

## Technical Field

The present invention relates to a new vector system to facilitate the cloning and functional analysis of new genes
10   of a fly, *Drosophila melanogaster*, and a method for gene trapping with the vector system.

## Background Art

There are numerous examples for application of gene
15   trapping methods in wide range of living organisms including maize and mouse (Gossler et al,. Science, 244:463-465, 1989).

With respect to tools for gene trapping, the application of different types of enhancer trap P-element vectors (Wilson et al., Genes & Development, 3:1301-1313,
20   1989) for cloning and analyzing trapped genes, as well their use for mosaic analysis with the help of the Gal4/UAS transcription activator system has proven fruitful. However, sometimes the expression pattern of the Gal4 or other reporter gene of the vector construct is affected by
25   enhancers belonging to more than one gene. Similarly, in some cases it is difficult to determine whether the enhancer trap insertion effects the function of one or more of the neighboring genes.

These circumstances altogether with the fact that in
30   some cases the mutant phenotype could be attributed to the

changed expression of a gene with its nearest exon located more than 30 kB apart from the insertion site, can lead in unfortunate cases to an ordeal when it's time to clone and analyze the affected gene.

5    One object of this application is to provide a vector system that includes specifically designed artificial regulatory sequences as well as selection methods for easy screening of positive recombinant lines. More especially, this application intends to provide a vector system of this

10   invention offering much easier and faster cloning opportunities of the affected gene, compared to the widely used enhancer trap P-element vectors. Another object of this application is to provide easier detection method possibilities of the successful trapping events and much

15   higher chance to get more characteristic ("functional") expression patterns of the reporter gene because in the contrary with much of the cases with enhancer trap lines, when using the vector system of this invention, the reporter gene expression is influenced only by a single endogenous

20   transcription unit and effects only the expression of the very same gene.


## Disclosure of Invention

The first invention of this application is a vector for

25   trapping an unknown gene of *Drosophila melanogaster*, which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic "stop/start" sequence;

30   a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site.

5          One embodiment of the first invention is that the recombinant plasmid is derived from pCasper3.

Other embodiments of the first invention are that the reporter gene is the Gal4 gene, Gal4 DNA binding domain-P53 fusion gene or the Gal4-firefly luciferase fusion gene.

10         Further embodiment of this first invention is that the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene.

More further embodiment of the first invention is that the drug resistance gene is neomycin-phosphotranspherase gene 15 and its promoter is a heatshock promoter.


The second invention of this application is a method for trapping an unknown gene of *Drosophila melanogaster* by using a vector which is a recombinant plasmid comprising the 20 following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic "stop/start" sequence;

a reporter gene;

a drug resistance gene;

25   a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site,

which method comprises the steps of:

(a)   introducing the vector into the genome of a white minus 30   fly;

(b)    selecting primary transformants resistant to a drug;

(c)    crossing the primary transformants with a transposase source strain to force the vector to jump into other locations;

5    (d)    selecting secondary transformants by picking up the flies having strong eye color,

(e)    crossing the secondary transformants with UAS (Upstream Activator Sequence)-luciferase harboring strain and measuring the reporter gene expression of the resultant flies; and

10    (f)    identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.


The third invention of this application is a method for
15    trapping an unknown gene of *Drosophila melanogaster* by using a vector A which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic "stop/start" sequence;

20    Gal4 DNA binding domain-P53 fusion gene as a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site,

25    and a vector B derived from pCasperhs, which has the heatshock promoter directed Gal4 activator domain-large T antigen fusion gene within polycloning site of the pCasperhs, which method comprises the steps of:

(a)    introducing each of the vectors A and B into the
30    genomes of separate white minus flies;

(b)    selecting primary transformants for the vector A which are resistant to the drug, and selecting primary transformants for the vector B which have an eye color;

(c)    crossing the primary transformants for the vector A with a transposase source strain to force the vector to jump into other locations;

(d)    selecting secondary transformants for the vector A by picking up the flies having strong eye color;

(e)    crossing the secondary transformants with the primary transformants for the vector B to obtain flies harboring both the vectors A and B;

(f)    crossing the flies obtained in the step (e) with an UAS-luciferase harboring fly strain and measuring the reporter gene expression of the resultant flies after a heatshock treatment; and

(g)    identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.


Embodiments of the second and third inventions are corresponded to the embodiments of the first invention, and they will be more precisely described in the following description.


Brief Description of Drawings

Figure 1 shows the schematic map of the vector of this invention, pTrap-hsneo.

Figure 2 shows the schematic map of the vector of this invention, pTrap-G4-p53.

Figure 3 shows the schematic map of the vector of this

invention, pCasperhs-G4-LT.

Figure 4 shows the schematic map of the vector of this invention, pTrap-G4-luc.

Figure 5 shows the shematic drawing of a fly genome to which the vector of this invention is inserted for cloning.

Figure 6 shows the results of sequencing RT-PCR products of aop-Gal4 and m-white-aop fusion mRNAs.

Figure 7 presents pictures of characteristic beta-galactosidase staining patterns in different parts of the fly brain resulted from crossing positive gene trap lines with flies harboring a UAS-lacZ construct.


## Best Mode for Carrying Out the Invention

A vector construct of the first invention, for example, can be based on the commonly used, P-element transformation vector, pCasper3 (Pirotta, Vectors: A survey of molecular cloning vectors and their uses, eds. Rodriguez, R.L. & Denhardt, D.T., Butterworths, Boston. 437-456, 1998) and the convenient Gal4-UAS expression system (Brand and Perrimon, Development, 118:401-415, 1993).

A promoterless Gal4 gene preceded by an artificial consensus splicing acceptor site and a synthetic "stop/start" sequence to govern the read through translation coming from upstream exon(s) of the trapped gene into the proper reading frame of Gal4 was inserted into the polycloning site of pCasper3.

The removal of the whole 3′ UTR (untranslated region) sequence of the mini-white gene and replacement by an artificial splicing donor site resulted in a truncated gene without its own poly-adenylation site.

Without a successful gene trapping event this truncated mini-white gene was not expected to confer any eye color, therefore in this invention a heatshock promoter directed neomycin-phosphotransferase (hs-neo) gene for helping

5   selection of primary transformants by antibiotic feeding has been inserted.

Figure 1 shows the schematic map of the gene trap construct (pTrap-hsneo), and SEQ ID No.1 is the complete nucleotide sequence of the vector pTrap-hsneo.

10  Another gene trap construct, pTrap-G4-p53 (Figure 2) is created by replacing the Gal4 coding sequence of plasmid pTrap-hsneo with a Gal4 DNA binding domain-P53 fusion gene (Clontech, Matchmaker Two Hybrid System, #K1605-1). When this construct coexists in the genome of the same fly with another

15  vector, pCasperhs-G4-LT (Figure 3) containing a heatshock promoter directed Gal4 activator domain-large T antigen (Clontech, Matchmaker Two Hybrid System, #K1605-1) fusion gene, the assembly of a functional Gal4 molecule, through p53-large T antigen interaction, can be regulated by external

20  heatshock.

On this way, the possibility of an intentional temporary control of Gal4 activity became available. In other words the Gal4 expression in a pattern as already determined spatially by the promoter of the trapped gene now can be

25  induced at any desired stage of development by external heatshock.

In order to make the detection of Gal4 expression easier, the Gal4 gene in another construct is replaced with a Gal4-firefly luciferase fusion gene to get pTrap-G4-luc

30  (Figure 4). This artificial gene is coding for a fusion

polypeptide which has preserved both enzymatic activities.

The easy measuring of luciferase activity by luminoassay (Brandes et al., Neuron, 16:687-694, 1996) makes the detection of Gal4 activity comfortable in every single

5 living fly.

Then, one of the best mode of the second or third invention, a method for gene trapping using the vector system, is described in detail.

10 (1) Screening:

The gene trap vector constructs can be introduced into the genome of a white minus fly by microinjection. The selection of primary transformants is possible by using G418, an analog of neomycin, resistance conferred by hs-neo gene.

15 (When performing transformation experiments with these constructs it's turned out that the truncated mini-white gene generally provides a very slight yellow eye color which could be distinguished from w-minus phenotype in most of the cases, therefore G418 selection apparently is not necessary.)

20 After a line with the gene trap construct is being established, the secondary transformants can be generated on the usual way by crossing the original line with a so-called jumpstarter containing the transposase expressing delta 2-3 genetic element.

25 Usually a certain percentage, between 4 and 8, of the secondary transformants have much stronger eye color (deep orange or reddish) than the ancestor fly indicating that the construct was being inserted downstream of a promoter and now the mini-white gene is using the transcriptional "facilities"

30 of that gene (e.g.: poly-adenylation site and transcriptional

terminator) instead of its removed ones. They are the most likely candidates for successful gene trap events. In case of these lines the vector probably has been inserted either into an intron of a gene or upstream from the first intron into the 5' UTR in proper orientation (that is the direction of transcription is same for the "trapped gene" and the mini-white (and Gal4) genes as well). The mini-white gene has its own promoter therefore its expression pattern is supposed to be largely independent from that of the trapped gene.

These positive lines are to be checked in the next step for Gal4 expression by crossing them with a "marker" line harboring a UAS-luciferase reporter gene construct. (When using pTrap-G4-luc vector, this step is obviously not necessary.) Usually very strong correlation was found between eye color and Gal4 expression: more than 90% of the lines having strong eye color proved to be expressing Gal4 by means of luciferase assay using luminometer (Brandes et al., Neuron, 16:687-692, 1996).

(2) Cloning:

When the gene trap construct is being inserted into an intron of an endogenous gene, the marker genes of the construct are supposed to be spliced on mRNA level to the exons of the trapped gene by using the artificial splicing acceptor and donor sites. More exactly while the Gal4 mRNA should be joint to the exon(s) located upstream of the insertion site, at the same time the mini-white mRNA is fused to the following exon(s) accomplishing the dual tagging of the trapped gene (Figure 5).

This feature can be used for quickly and easily

identifying the trapped gene by means of 3' and 5' RACE (Rapid Amplification of cDNA Ends) experiments. Even cloning and sequencing only a part of the caught mRNA still provides reasonable chance to find homologous mRNAs in the BDGP

5   (Berkeley Drosophila Genome Project) EST (Expressed Sequence Tag) library.

With these approaches, the identification of an already cloned gene can take less then a week compared to the usually more than one year period in average when analyzing a mutant

10  created by some enhancer trap construct.

It's well-known from the literature and the present inventors also have experienced that P-element vectors tend to integrate into or near the 5' UTR of active genes. (The present inventors found that in these cases if the insertion

15  occurred upstream from the first intron, and therefore the artificial splicing acceptor site could not be utilized, the Gal4 gene was expressed by read-through transcription from the nearby promoter.)

The advantage of this tendency can be taken by cloning

20  and sequencing the flanking genomic sequences of the insertion site by inverse or vectorette PCR or by plasmid rescue using suitable restriction digestion to recover the neomycin resistance gene of the construct. Then again the BDGP library can be searched to find any significant matching.

25

(3) Rescue:

The only reliable way to confirm that any observed mutant phenotype is really the consequence of the P-element insertion is to rescue that particular phenotype. Expectedly

30  the phenotype (some alteration from wild type fly) is caused

by changed expression of gene(s) disturbed by insertion of the P-element. The rescue can be made by expressing the cDNA of the suspected gene most preferable with identical spatial and temporary pattern than that of the gene itself.

5       As it was expected, the vector constructs of the first invention usually cause strong phenotypes. It's not surprising at all because the trapped genes are supposed to be split into two parts on mRNA level resulting in null mutants in majority of the cases. Accordingly mutants

10     obtained by this method frequently show homozygous lethality or sterility. Hypomorphic mutants can be obtained by forcing imprecise excision of the gene trap P-element construct.

As mentioned above, the Gal4 expression is obliged to reflect precisely to that of the trapped gene simply because

15     the Gal4 gene has no its own promoter and they share a common, fused mRNA.

This identical expression provides unique opportunity to rescue the mutant phenotype by crossing this fly with another one harboring the UAS directed, cloned cDNA of the

20     trapped gene.

On this way either the original, homozygous null mutant gene trap fly or any transheterozygous derivative of that with some hypomorphic allele over the null mutant allele can be rescued.

25

(4) Determination of spatial and developmental expression
       pattern of the trapped gene:

Histochemical determination of the spatially and temporarily controlled expression of any trapped gene is also

30     easy following introduction of a UAS-lacZ construct into the

genome of the same fly and performing either X-gal or antibody staining for beta-galactosidase.

(5) Mosaic analysis:

Possession of a large collection of fly lines with different, characteristic and, in the case of the pTrap-G4-p53/pCasperhs-G4-TL vector system, inducible Gal4 expression pattern makes feasible carrying out mosaic analysis of virtually any gene of interest by directing the expression of their UAS-constructs on a mutant background with different Gal4 expression patterns.

This approach can answer the question of where and when that particular gene is required to be expressed to rescue the mutant phenotype.

Similarly, any gene can be expressed in different ectopic patterns to generate new dominant mutant phenotypes. This approach might help to conclude the role of that particular gene and to identify the pathway, in which it's involved.

## Example

The following example illustrates a specific embodiment of the various aspects of the invention. This example is not intended to limit the invention in any manner.

Figure 6 shows the results of sequencing RT-PCR products of aop-Gal4 and m-white-aop fusion mRNAs.

The template was total RNA prepared from a positive gene trap line which has the vector pTrap-hsneo being integrated into the first intron of the well-known aop (anterior open/pokkuri/yan) developmental gene. The sequences confirm that both splicing occurred precisely at that

particular nucleotides of the artificial regulatory sequences where it was expected.

On Figure 7, there are pictures of characteristic beta-galactosidase staining patterns in different parts of the fly 5 brain resulted from crossing positive gene trap lines with flies harboring a UAS-lacZ construct.

## Industrial Applicability

The vector system of this invention offers an 10 exceptional opportunity for easy and fast cloning of the gene responsible for the observed phenotype. Furthermore, by using the UAS-driven coding sequence of any gene of interest, that particular gene can be expressed in identical patterns than those of the trapped genes and these expressions can be 15 regulated temporarily at any desired developmental stage.

## Sequence Listing

<110> Japan Science and Technology Corporation

<120> A Vector for Gene Trap, and A Method for Gene Trapping
20      by Using The Vector

<150> Japan, Application No. 10-141952

<151> 22 May 1998

<160> 1

<170> PatentIn Ver. 2.0

25 <210> 1

<211> 11206

<212> DNA

<213> Artificial sequence

<220>

30 <221> 3' P sequence

&lt;222&gt;  (1)..(237)

&lt;220&gt;

&lt;221&gt;  synthetic  splicing  acceptor  site  and  stop/start
sequence

5    &lt;222&gt;  (238)..(274)

&lt;220&gt;

&lt;221&gt;  Gal4 gene (coding region and 3'UTR)

&lt;222&gt;  (275)..(3164)

&lt;220&gt;

10    &lt;221&gt;  hsp70 terminator

&lt;222&gt;  (3165)..(3426)

&lt;220&gt;

&lt;221&gt;  synthetic junction sequence

&lt;222&gt;  3427-3457

15    &lt;220&gt;

&lt;221&gt;  heat shock promoter directed neomycine resistance gene
on complementer strand

&lt;222&gt;  (3458)..(4907)

&lt;220&gt;

20    &lt;221&gt;  mini-white gene

&lt;222&gt;  (4908)..(8275)

&lt;220&gt;

&lt;221&gt;  synthetic splicing donor site

&lt;222&gt;  (8276)..(8299)

25    &lt;220&gt;

&lt;221&gt;  5'P sequence

&lt;222&gt;  (8300)..(8446)

&lt;220&gt;

&lt;221&gt;  bacterial part of pCasper3 shuttle vector including
30    complete pUC8 sequence

```
<222>   (8447)..(11206)

<220>

<221>   synthetic DNA

<222>   (238)..(274)

        (3427)..(3457)

        (4908)..(4914)

        (8276)..(8299)

<400>   1

catgatgaaa taacataagg tggtcccgtc ggcaagagac atccacttaa cgtatgcttg    60

caataagtgc gagtgaaagg aatagtattc tgagtgtcgt attgagtctg agtgagacag    120

cgatatgatt gttgattaac ccttagcatg tccgtggggt ttgaattaac tcataatatt    180

aattagacga aattattttt aaagttttat ttttaataat ttgcgagtac gcaaagctct    240

ttctcttaca ggtcgaattg atgtgatgga tccaatgaag ctactgtctt ctatcgaaca    300

agcatgcgat atttgccgac ttaaaaagct caagtgctcc aaagaaaaac cgaagtgcgc    360

caagtgtctg aagaacaact gggagtgtcg ctactctccc aaaaccaaaa ggtctccgct    420

gactagggca catctgacag aagtggaatc aaggctagaa agactggaac agctatttct    480

actgattttt cctcgagaag accttgacat gattttgaaa atggattctt tacaggatat    540

aaaagcattg ttaacaggat tatttgtaca agataatgtg aataaagatg ccgtcacaga    600

tagattggct tcagtggaga ctgatatgcc tctaacattg agacagcata gaataagtgc    660

gacatcatca tcggaagaga gtagtaacaa aggtcaaaga cagttgactg tatcgattga    720

ctcggcagct catcatgata actccacaat tccgttggat tttatgccca gggatgctct    780

tcatggattt gattggtctg aagaggatga catgtcggat ggcttgccct tcctgaaaac    840

ggaccccaac aataatgggt tctttggcga cggttctctc ttatgtattc ttcgatctat    900

tggctttaaa ccggaaaatt acacgaactc taacgttaac aggctcccga ccatgattac    960

ggatagatac acgttggctt ctagatccac aacatcccgt ttacttcaaa gttatctcaa    1020

taattttcac ccctactgcc ctatcgtgca ctcaccgacg ctaatgatgt tgtataataa    1080

ccagattgaa atcgcgtcga aggatcaatg gcaaatcctt tttaactgca tattagccat    1140

tggagcctgg tgtatagagg gggaatctac tgatatagat gttttttact atcaaaatgc    1200

taaatctcat ttgacgagca aggtcttcga gtcaggttcc ataattttgg tgacagccct    1260

acatcttctg tcgcgatata cacagtggag gcagaaaaca aatactagct ataattttca    1320
```

```
      cagctttttcc ataagaatgg ccatatcatt gggcttgaat aggggacctcc cctcgtcctt   1380

      cagtgatagc agcattctgg aacaaagacg ccgaatttgg tggtctgtct actcttggga   1440

      gatccaattg tccctgcttt atggtcgatc catccagctt tctcagaata caatctcctt   1500

      cccttcttct gtcgacgatg tgcagcgtac cacaacaggt cccaccatat atcatggcat   1560

 5    cattgaaaca gcaaggctct tacaagtttt cacaaaaatc tatgaactag acaaaacagt   1620

      aactgcagaa aaaagtccta tatgtgcaaa aaaatgcttg atgatttgta atgagattga   1680

      ggaggtttcg agacaggcac caaagttttt acaaatggat atttccacca ccgctctaac   1740

      caatttgttg aaggaacacc cttggctatc ctttacaaga ttcgaactga agtggaaaca   1800

      gttgtctctt atcatttatg tattaagaga ttttttcact aattttaccc agaaaaagtc   1860

10    acaactagaa caggatcaaa atgatcatca aagttatgaa gttaaacgat gctccatcat   1920

      gttaagcgat gcagcacaaa gaactgttat gtctgtaagt agctatatgg acaatcataa   1980

      tgtcaccccca tattttgcct ggaattgttc ttattacttg ttcaatgcag tcctagtacc   2040

      cataaagact ctactctcaa actcaaaatc gaatgctgag aataacgaga ccgcacaatt   2100

      attacaacaa attaacactg ttctgatgct attaaaaaaa ctggccactt ttaaaatcca   2160

15    gacttgtgaa aaatacattc aagtactgga agaggtatgt gcgccgtttc tgttatcaca   2220

      gtgtgcaatc ccattaccgc atatcagtta taacaatagt aatggtagcg ccattaaaaa   2280

      tattgtcggt tctgcaacta tcgcccaata ccctactctt ccggaggaaa atgtcaacaa   2340

      tatcagtgtt aaatatgttt ctcctggctc agtagggcct tcacctgtgc cattgaaatc   2400

      aggagcaagt ttcagtgatc tagtcaagct gttatctaac cgtccaccct ctcgtaactc   2460

20    tccagtgaca ataccaagaa gcacaccttc gcatcgctca gtcacgcctt ttctagggca   2520

      acagcaacag ctgcaatcat tagtgccact gaccccgtct gctttgtttg gtggcgccaa   2580

      tttttaatcaa agtgggaata ttgctgatag ctcattgtcc ttcactttca ctaacagtag   2640

      caacggtccg aacctcataa caactcaaac aaattctcaa gcgctttcac aaccaattgc   2700

      ctcctctaac gttcatgata acttcatgaa taatgaaatc acggctagta aaattgatga   2760

25    tggtaataat tcaaaaccac tgtcacctgg ttggacggac caaactgcgt ataacgcgtt   2820

      tggaatcact acagggatgt ttaataccac tacaatggat gatgtatata actatctatt   2880

      cgatgatgaa gataccccac caaacccaaa aaaagagtaa aatgaatcgt agatactgaa   2940

      aaaccccgca agttcacttc aactgtgcat cgtgcaccat ctcaatttct ttcatttata   3000

      catcgttttg ccttctttta tgtaactata ctcctctaag tttcaatctt ggccatgtaa   3060

30    cctctgatct atagaatttt ttaaatgact agaattaatg cccatctttt ttttggacct   3120
```

```
        aaattcttca tgaaaatata ttacgagggc ttattcagaa gcttatcgat accgtcgact    3180

        aaagccaaat agaaattatt cagttctggc ttaagttttt aaaagtgata ttatttattt    3240

        ggttgtaacc aaccaaaaga atgtaaataa ctaatacata attatgttag tttttaagtta   3300

        gcaacaaatt gattttagct atattagcta cttggttaat aaatagaata tatttatttta   3360

   5    aagataattc gtttttattg tcagggagtg agtttgctta aaaactcgtt tagatccact    3420

        agaaggaccg cggctcctcg accggatcga aaggagggcg aagaactcca gcatgagatc    3480

        cccgcgctgg aggatcatcc agccggcgtc ccggaaaacg attccgaagc ccaacctttc    3540

        atagaaggcg gcggtggaat cgaaatctcg tgatggcagg ttgggcgtcg cttggtcggt    3600

        catttcgaac cccagagtcc cgctcagaag aactcgtcaa gaaggcgata gaaggcgatg    3660

  10    cgctgcgaat cgggagcggc gataccgtaa agcacgagga agcggtcagc ccattcgccg    3720

        ccaagctctt cagcaatatc acgggtagcc aacgctatgt cctgatagcg gtccgccaca    3780

        cccagccggc cacagtcgat gaatccagaa aagcggccat tttccaccat gatattcggc    3840

        aagcaggcat cgccatgggt cacgacgaga tcctcgccgt cgggcatgcg cgccttgagc    3900

        ctggcgaaca gttcggctgg cgcgagcccc tgatgctctt cgtccagatc atcctgatcg    3960

  15    acaagaccgg cttccatccg agtacgtgct cgctcgatgc gatgtttcgc ttggtggtcg    4020

        aatgggcagg tagccggatc aagcgtatgc agccgccgca ttgcatcagc catgatggat    4080

        actttctcgg caggagcaag gtgagatgac aggagatcct gccccggcac ttcgcccaat    4140

        agcagccagt cccttcccgc ttcagtgaca acgtcgagca cagctgcgca aggaacgccc    4200

        gtcgtggcca gccacgatag ccgcgctgcc tcgtcctgca gttcattcag ggcaccggac    4260

  20    aggtcggtct tgacaaaaag aaccgggcgc ccctgcgctg acagccggaa cacggcggca    4320

        tcagagcagc cgattgtctg ttgtgcccag tcatagccga atagcctctc cacccaagcg    4380

        gccggagaac ctgcgtgcaa tccatcttgt tcaatcatgc gaaacgatcc tcatcctgtc    4440

        tcttgatcag atcccctatt cagagttctc ttcttgtatt caataattac ttcttggcag    4500

        atttcagtag ttgcagttga tttacttggt tgctggttac ttttaattga ttcactttaa    4560

  25    cttgcacttt actgcagatt gtttagcttg ttcagctgcg cttgtttatt tgcttagctt    4620

        tcgcttagcg acgtgttcac tttgcttgtt tgaattgaat tgtcgctccg tagacgaagc    4680

        gcctctattt atactccggc gctcttttcg cgaacattcg aggcgcgctc tctcgaacca    4740

        acgagagcag tatgccgttt actgtgtgac agagtgagag agcattagtg cagagaggga    4800

        gagacccaaa aagaaaagag agaataacga ataacggcca gagaaatttc tcgagttttc    4860

  30    tttctgccaa acaaatgacc taccacaata accagtttgt tttgggatct agtccctaat    4920
```

```
tctagtatgt atgtaagtta ataaaaccct tttttggaga atgtagattt aaaaaaacat    4980

attttttttt tatttttttac tgcactggac atcattgaac ttatctgatc agttttaaat    5040

ttacttcgat ccaagggtat ttgaagtacc aggttctttc gattacctct cactcaaaat    5100

gacattccac tcaaagtcag cgctgtttgc ctccttctct gtccacagaa atatcgccgt    5160

ctctttcgcc gctgcgtccg ctatctcttt cgccaccgtt tgtagcgtta cctagcgtca    5220

atgtccgcct tcagttgcac tttgtcagcg gtttcgtgac gaagctccaa gcggtttacg    5280

ccatcaatta aacacaaagt gctgtgccaa aactcctctc gcttcttatt tttgtttgtt    5340

ttttgagtga ttggggtggt gattggtttt gggtgggtaa gcaggggaaa gtgtgaaaaa    5400

tcccggcaat gggccaagag gatcaggagc tattaattcg cggaggcagc aaacacccat    5460

ctgccgagca tctgaacaat gtgagtagta catgtgcata catcttaagt tcacttgatc    5520

tataggaact gcgattgcaa catcaaattg tctgcggcgt gagaactgcg acccacaaaa    5580

atcccaaacc gcaatcgcac aaacaaatag tgacacgaaa cagattattc tggtagctgt    5640

gctcgctata taagacaatt tttaagatca tatcatgatc aagacatcta aaggcattca    5700

ttttcgacta cattcttttt tacaaaaaat ataacaacca gatattttaa gctgatccta    5760

gatgcacaaa aaataaataa aagtataaac ctacttcgta ggatacttcg ttttgttcgg    5820

ggttagatga gcataacgct tgtagttgat atttgagatc ccctatcatt gcagggtgac    5880

agcggacgct tcgcagagct gcattaacca gggcttcggg caggccaaaa actacggcac    5940

gctcctgcca cccagtccgc cggaggactc cggttcaggg agcggccaac tagccgagaa    6000

cctcacctat gcctggcaca atatggacat ctttggggcg gtcaatcagc cgggctccgg    6060

atggcggcag ctggtcaacc ggacacgcgg actattctgc aacgagcgac acataccggc    6120

gcccaggaaa catttgctca agaacggtga gtttctattc gcagtcggct gatctgtgtg    6180

aaatcttaat aaagggtcca attaccaatt tgaaactcag tttgcggcgt ggcctatccg    6240

ggcgaacttt tggccgtgat gggcagttcc ggtgccggaa agacgaccct gctgaatgcc    6300

cttgcctttc gatcgccgca gggcatccaa gtatcgccat ccgggatgcg actgctcaat    6360

ggccaacctg tggacgccaa ggagatgcag gccaggtgcg cctatgtcca gcaggatgac    6420

ctctttatcg gctccctaac ggccagggaa cacctgattt tccaggccat ggtgcggatg    6480

ccacgacatc tgacctatcg gcagcgagtg gcccgcgtgg atcaggtgat ccaggagctt    6540

tcgctcagca aatgtcagca cacgatcatc ggtgtgcccg gcagggtgaa aggtctgtcc    6600

ggcggagaaa ggaagcgtct ggcattcgcc tccgaggcac taaccgatcc gccgcttctg    6660

atctgcgatg agcccacctc cggactggac tcatttaccg cccacagcgt cgtccaggtg    6720
```

```
      ctgaagaagc tgtcgcagaa gggcaagacc gtcatcctga ccattcatca gccgtcttcc   6780

      gagctgtttg agctctttga caagatcctt ctgatggccg agggcagggt agctttcttg   6840

      ggcactccca gcgaagccgt cgacttcttt tcctagtgag ttcgatgtgt ttattaaggg   6900

      tatctagcat tacattacat ctcaactcct atccagcgtg ggtgcccagt gtcctaccaa   6960

    5 ctacaatccg gcggactttt acgtacaggt gttggccgtt gtgcccggac gggagatcga   7020

      gtcccgtgat cggatcgcca agatatgcga caattttgct attagcaaag tagcccggga   7080

      tatggagcag ttgttggcca ccaaaaattt ggagaagcca ctggagcagc cggagaatgg   7140

      gtacacctac aaggccacct ggttcatgca gttccgggcg gtcctgtggc gatcctggct   7200

      gtcggtgctc aaggaaccac tcctcgtaaa agtgcgactt attcagacaa cggtgagtgg   7260

   10 ttccagtgga aacaaatgat ataacgctta caattcttgg aaacaaattc gctagatttt   7320

      agttagaatt gcctgattcc acacccttct tagttttttt caatgagatg tatagtttat   7380

      agttttgcag aaaataaata aatttcattt aactcgcgaa catgttgaag atatgaatat   7440

      taatgagatg cgagtaacat tttaatttgc agatggttgc catcttgatt ggcctcatct   7500

      ttttgggcca acaactcacg caagtgggcg tgatgaatat caacggagcc atcttcctct   7560

   15 tcctgaccaa catgaccttt caaaacgtct ttgccacgat aaatgtaagt cttgtttaga   7620

      atacatttgc atattaataa tttactaact ttctaatgaa tcgattcgat ttaggtgttc   7680

      acctcagagc tgccagtttt tatgagggag gcccgaagtc gactttatcg ctgtgacaca   7740

      tactttctgg gcaaaacgat tgccgaatta ccgctttttc tcacagtgcc actggtcttc   7800

      acggcgattg cctatccgat gatcggactg cgggccggag tgctgcactt cttcaactgc   7860

   20 ctggcgctgg tcactctggt ggccaatgtg tcaacgtcct tcggatatct aatatcctgc   7920

      gccagctcct cgacctcgat ggcgctgtct gtgggtccgc cggttatcat accattcctg   7980

      ctctttggcg gcttcttctt gaactcgggc tcggtgccag tatacctcaa atggttgtcg   8040

      tacctctcat ggttccgtta cgccaacgag ggtctgctga ttaaccaatg ggcggacgtg   8100

      gagccgggcg aaattagctg cacatcgtcg aacaccacgt gccccagttc gggcaaggtc   8160

   25 atcctggaga cgcttaactt ctccgccgcc gatctgccgc tggactacgt gggtctggcc   8220

      attctcatcg tgagcttccg ggtgctcgca tatctggctc taagacttcg ggcccgacgc   8280

      aaggagtaga aggtaagtag cggccgcacg taagggttaa tgttttcaaa aaaaaattcg   8340

      tccgcacaca accttttcctc tcaacaagca aacgtgcact gaatttaagt gtatacttcg   8400

      gtaagcttcg gctatcgacg ggaccacctt atgttatttc atcatgggcc agacccacgt   8460

   30 agtccagcgg cagatcggcg gcggagaagt taagcgtctc caggatgacc ttgcccgaac   8520
```

```
     tggggcacgt ggtgttcgac gatgtgcagc taatttcgcc cggctccacg tccgcccatt  8580

     ggttaatcag cagaccctcg ttggcgtaac ggaaccatga gaggtacgac aaccatttga  8640

     ggtatactgg caccgagccc gagttcaaga agaaggcgtt tttccatagg ctccgccccc  8700

     ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat  8760

 5   aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc  8820

     cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcaatgct  8880

     cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg  8940

     aacccccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc  9000

     cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga  9060

10   ggtatgtagg cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa  9120

     ggacagtatt tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta  9180

     gctcttgatc cggcaaacaa accaccgctg gtagcggtgg ttttttttgtt tgcaagcagc  9240

     agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg  9300

     acgctcagtg gaacgaaaac tcacgttaag ggattttggt catgagatta tcaaaaagga  9360

15   tcttcaccta gatcctttta aattaaaaat gaagttttaa atcaatctaa agtatatatg  9420

     agtaaacttg gtctgacagt taccaatgct taatcagtga ggcacctatc tcagcgatct  9480

     gtctatttcg ttcatccata gttgcctgac tccccgtcgt gtagataact acgatacggg  9540

     agggcttacc atctggcccc agtgctgcaa tgataccgcg agacccacgc tcaccggctc  9600

     cagatttatc agcaataaac cagccagccg gaagggccga gcgcagaagt ggtcctgcaa  9660

20   ctttatccgc ctccatccag tctattaatt gttgccggga agctagagta agtagttcgc  9720

     cagttaatag tttgcgcaac gttgttgcca ttgctacagg catcgtggtg tcacgctcgt  9780

     cgtttggtat ggcttcattc agctccggtt cccaacgatc aaggcgagtt acatgatccc  9840

     ccatgttgtg caaaaaagcg gttagctcct tcggtcctcc gatcgttgtc agaagtaagt  9900

     tggccgcagt gttatcactc atggttatgg cagcactgca taattctctt actgtcatgc  9960

25   catccgtaag atgcttttct gtgactggtg agtactcaac caagtcattc tgagaatagt 10020

     gtatgcggcg accgagttgc tcttgcccgg cgtcaacacg gataataccc gcgccacata 10080

     gcagaacttt aaaagtgctc atcattggaa aacgttcttc ggggcgaaaa ctctcaagga 10140

     tcttaccgct gttgagatcc agttcgatgt aacccactcg tgcacccaac tgatcttcag 10200

     catcttttac tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa 10260

30   aaaagggaat aagggcgaca cggaaatgtt gaatactcat actcttcctt tttcaatatt 10320
```

```
     attgaagcat ttatcagggt tattgtctca tgagcggata catatttgaa tgtatttaga   10380

     aaaataaaca aataggggtt ccgcgcacat ttccccgaaa agtgccacct gacgtctaag   10440

     aaaccattat tatcatgaca ttaacctata aaaataggcg tatcacgagg ccctttcgtc   10500

     tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca   10560

  5  cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg   10620

     ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc   10680

     accatatgcg gtgtgaaata ccgcaccgaa tcgcgcggaa ctaacgacag tcgctccaag   10740

     gtcgtcgaac aaaaggtgaa tgtgttgcgg agagcgggtg ggagacagcg aaagagcaac   10800

     tacgaaacgt ggtgtggtgg aggtgaatta tgaagagggc gcgcgatttg aaaagtatgt   10860

 10  atataaaaaa tatatcccgg tgttttatgt agcgataaac gagtttttga tgtaaggtat   10920

     gcaggtgtgt aagtcttttg gttagaagac aaatccaaag tctacttgtg gggatgttcg   10980

     aaggggaaat acttgtattc tataggtcat atcttgtttt tattggcaca aatataatta   11040

     cattagcttt ttgagggggc aataaacagt aaacacgatg gtaataatgg taaaaaaaaa   11100

     aacaagcagt tatttcggat atatgtcggc tactccttgc gtcgggcccg aagtcttaga   11160

 15  gccagatatg cgagcacccg gaagctcacg atgagaatgg ccagac              11206
```

CLAIMS

1.    A vector for trapping an unknown gene of *Drosophila melanogaster*, which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic "stop/start" sequence;

a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site.


2.    The vector of claim 1, wherein the recombinant plasmid is derived from pCasper3.


3.    The vector of claim 1 or 2, wherein the reporter gene is the Gal4 gene.


4.    The vector of claim 3, which has the nucleotide sequence of SEQ ID No. 1.


5.    The vector of claim 1 or 2, wherein the reporter gene is Gal4 DNA binding domain-P53 fusion gene.

6.    The vector of claim 1 or 2, wherein the reporter gene is the Gal4-firefly luciferase fusion gene.


7.    The vector of any one of claims 1-6, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene.

8. The vector of any one of claims 1-7, wherein the drug resistance gene is neomycin-phosphotranspherase gene and its promoter is a heatshock promoter.

5

9 A vector derived from pCasperhs, which has the heatshock promoter directed Gal4 activator domain-large T antigen fusion gene within polycloning site of the pCasperhs.

10    10. A method for trapping an unknown gene of *Drosophila melanogaster* by using a vector which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic "stop/start" sequence;

15    a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site,

20        which method comprises the steps of:

(a)    introducing the vector into the genome of a white minus fly;

(b)    selecting primary transformants resistant to a drug;

(c)    crossing the primary transformants with a transposase

25    source strain to force the vector to jump into other locations;

(d)    selecting secondary transformants by picking up the flies having strong eye color,

(e)    crossing the secondary transformants with UAS (Upstream

30    Activator Sequence)-luciferase harboring strain and measuring

the reporter gene expression of the resultant flies; and

(f)   identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.

11.   The method according to claim 10, wherein the recombinant plasmid is derived from pCasper3.

12.   The method according to claim 10 or 11, wherein the reporter gene in the vector is the Gal4 gene, and in the step (e) the Gal4 expression is measured.

13.   The method according to claim 10 or 11, wherein the reporter gene of the vector is the Gal4-firefly luciferase fusion gene, and in the step (e) expression of said fusion gene is measured without crossing the secondary transformants with UAS-luciferase harboring strain.

14.   The method according to any one of claims 10 to 14, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene, and in the step (f) the cDNAs fused to the reporter gene and the mini-white gene are cloned and sequenced.

15.   The method according to any one of claims 10 to 15, wherein the drug resistance gene is neomycin-phosphotranspherase gene and its promoter is a heatshock promoter, and in the step (b) the transformants resistant to G418 is selected.

16.   A method for trapping an unknown gene of *Drosophila*

*melanogaster* by using a vector A which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

5       a synthetic "stop/start" sequence;

Gal4 DNA binding domain-P53 fusion gene as a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

10      a synthetic splicing donor site,

and a vector B derived from pCasperhs, which has the heatshock promoter directed Gal4 activator domain-large T antigen fusion gene within polycloning site of the pCasperhs,

which method comprises the steps of:

15      (a)   introducing each of the vectors A and B into the genomes of separate white minus flies;

(b)   selecting primary transformants for the vector A which are resistant to a drug, and selecting primary transformants for the vector B which have an eye color;

20      (c)   crossing the primary transformants for the vector A with a transposase source strain to force the vector to jump into other locations;

(d)   selecting secondary transformants for the vector A by picking up the flies having strong eye color;

25      (e)   crossing the secondary transformants with the primary transformants for the vector B to obtain flies harboring both the vectors A and B;

(f)   crossing the flies obtained in the step (e) with an UAS-luciferase harboring fly strain and measuring the

30      reporter gene expression of the resultant flies after a

heatshock treatment; and

(g)   identifying the trapped gene by cloning and sequencing
the cDNAs fused to the reporter gene and the gene responsible
for a detectable phenotype of the fly.

5

17.   The method according to claim 16, wherein the vector A
is derived from pCasper3.

18.   The method according to claim 16 or 17, wherein the
10   gene responsible for a detectable phenotype of the *Drosophila
melanogaster* is mini-white gene, and in the step (g) the
cDNAs fused to the reporter gene and the mini-white gene are
cloned and sequenced.

15   19.   The method according to any one of claims 16 to 18,
wherein   the   drug   resistance   gene   is   neomycin-
phosphotranspherase gene and its promoter is a heatshock
promoter, and in the step (b) the transformant resistant to
G418 is selected.

Fig. 1

Fig. 2

Fig. 3



3'P
hsp70 term.

PUC8

Gal4-Large-T fusion gene

pCasperhs-G4-LT
10669 bp

hsp70 promoter

5'P

m-white

4/7

Fig. 4

## Fig. 5

Gene-Trap vector construct



m-RNA-s supposed to be expressed:

1.)

2.)

Proteins supposed to be expressed:

1.) Gal4 fused to preceeding (upstream or N-terminal) exons.
2.) m-white being expressed itself.

ABBREVIATIONS:

| | |
|---|---|
| 3'P, 5'P | flanking P-element sequences |
| A.S. | consensus splicing acceptor site |
| D.S. | consensus splicing donor site |
| f.s. | frame-shift signals for directing ribosomes translating the proper reading frame of Gal4 m-RNA (stop/start signal) |
| T | hs70 transcription terminator sequence and poly-A addition site |
| Neo | Neomycine resistance sequence for primary selection of transformants |
| GAL4 | promoterless Gal4 gene |
| m-white | mini-white gene with it's poly-A addition site having removed |

Fig. 6

Precise splicing of Gal4 and mini-white genes from Gene Trap vector
into anterior open gene

5'P end of vector; splice acceptor site/stop-start seq./Gal4 gene......mini-white gene/splice donor site; 3'P end of GT vector
......tttgcgagttcgcgaaagctcttctccttacag/gtcgaattgatgtgatgcaaatgaggt.........agactcggtcgcgtcgcgaaggaggtaggaag/gtaagtagcgtcccgaaacgtaaggcttaatg........

anterior open cDNA    exon 1                                         exon 2
cagtacgtaaccaccacagtgcacagtggagcaaacag/ataaacaccgcttaaaagcaattccagtggcttccac

anterior open exon 1 - Gal4 fusion cDNA
cagtacgtaaccaccacagtgcacagtggagcaaacag/gtcgaattgatgtgatgcaaatgaggt

mini-white - anterior open exon 2 fusion cDNA
agactcggtcgcgtcgcgaaggaggtaggaag/ataaacaccgcttaaaagcaattccagtggcttccac

Fig. 7

Gal4 expression patterns revealed by UAS-lacZ reporter construct.



A
line 77 adult brain

B
line 49 larval brain

C
line 6 larval brain

# DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original   () Supplemental   () Substitute   (X) PCT   () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: <u>A VECTOR FOR GENE TRAP, AND A METHOD FOR GENE TRAPPING BY USING THE VECTOR</u>

of which is described and claimed in:
() the attached specification, or
(X) the specification in application Serial No. ____NEW____, filed __November 21, 2000__, and with amendments through  (if applicable), or
(X) the specification in International Application No. <u>PCT/JP99/02683</u>, filed <u>May 21, 1999</u>, and as amended on  (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

| COUNTRY | APPLICATION NO. | DATE OF FILING | PRIORITY CLAIMED |
|---------|-----------------|----------------|------------------|
| Japan | 141952/1998 | May 22, 1998 | Yes |
|  |  |  | . |
|  |  |  | . |

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| APPLICATION SERIAL NO. | U.S. FILING DATE | STATUS: PATENTED, PENDING, ABANDONED |
|------------------------|------------------|--------------------------------------|
|  |  |  |
|  |  |  |

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nolton, Reg. No. 25,408; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., jointly and severally, attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from <u>NISHIZAWA & ASSOCIATES</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

WENDEROTH, LIND & PONACK, L.L.P.
2033 K Street, N.W., Suite 800
Washington, D.C. 20006

WENDEROTH, LIND & PONACK, L.L.P.
Area Code (202) 721-8200

Direct Facsimile Messages to:
Area Code (202) 721-8250

| Full Name of First Inventor | FAMILY NAME LUKACSOVICH | FIRST GIVEN NAME Tamas | SECOND GIVEN NAME | |
|---|---|---|---|---|
| Residence & Citizenship | CITY Tokyo | STATE OR COUNTRY Japan | COUNTRY OF CITIZENSHIP Hungary | |
| Post Office Address | ADDRESS 2-30-13, Narusedai, | CITY Machida-shi, Tokyo, Japan | STATE OR COUNTRY | ZIP CODE |

| Full Name of Second Inventor | FAMILY NAME ASZTALOS | FIRST GIVEN NAME Zoltan | SECOND GIVEN NAME | |
|---|---|---|---|---|
| Residence & Citizenship | CITY Tokyo | STATE OR COUNTRY Japan | COUNTRY OF CITIZENSHIP Hungary | |
| Post Office Address | ADDRESS 3-16-21, Narusedai, | CITY Machida-shi, Tokyo, Japan | STATE OR COUNTRY | ZIP CODE |

| Full Name of Third Inventor | FAMILY NAME YAMAMOTO | FIRST GIVEN NAME Daisuke | SECOND GIVEN NAME | |
|---|---|---|---|---|
| Residence & Citizenship | CITY Tokyo | STATE OR COUNTRY Japan | COUNTRY OF CITIZENSHIP Japan | |
| Post Office Address | ADDRESS 4-18-8, Narusedai, | CITY Machida-shi, Tokyo, Japan | STATE OR COUNTRY | ZIP CODE |

| Full Name of Fourth Inventor | FAMILY NAME AWANO | FIRST GIVEN NAME Wakae | SECOND GIVEN NAME | |
|---|---|---|---|---|
| Residence & Citizenship | CITY Kanagawa | STATE OR COUNTRY Japan | COUNTRY OF CITIZENSHIP Japan | |
| Post Office Address | ADDRESS Famiyu-102, 3-10-12, | CITY Minamidai, Sagamihara-shi, Kanagawa, Japan | STATE OR COUNTRY | ZIP CODE |

| Full Name of Fifth Inventor | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME | |
|---|---|---|---|---|
| Residence & Citizenship | CITY | STATE OR COUNTRY | COUNTRY OF CITIZENSHIP | |
| Post Office Address | ADDRESS | CITY | STATE OR COUNTRY | ZIP CODE |

| Full Name of Sixth Inventor | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME | |
|---|---|---|---|---|
| Residence & Citizenship | CITY | STATE OR COUNTRY | COUNTRY OF CITIZENSHIP | |
| Post Office Address | ADDRESS | CITY | STATE OR COUNTRY | ZIP CODE |

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor _____ Date January 1, 2001
Tamas LUKACSOVICH

2nd Inventor _____ Date January 1, 2001
Zoltan ASZTALOS

3rd Inventor _____ Date January 1, 2001
Daisuke YAMAMOTO

4th Inventor _____ Date January 1, 2001
Wakae AWANO

5th Inventor _____ Date _____

6th Inventor _____ Date _____

The above application may be more particularly identified as follows:

U.S. Application Serial No. ____NEW____ Filing Date ___November 21, 2000___

Applicant Reference Number _99-F-032/PCT-US/YS_ Atty Docket No._2000-1561A_

Title of Invention A VECTOR FOR GENE TRAP, AND A METHOD FOR GENE TRAPPING BY USING THE VECTOR